Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

PR Newswire  | 
A-
A+
Lesemodus
playAudio
playTeilen
Ein Business-Meeting (Symbolbild).
- © gilaxia / E+ / Getty Images

PR Newswire

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates.

QuidelOrtho Science Bytes | Episode 61

Hosted by Josh Casey, this episode features QuidelOrtho's Medical Science Liaison Chris Sanchez, MSN, RN, who brings to light diagnostic strategies necessary to support critically ill patients. Chris brings firsthand experience implementing diagnostic strategies as well as caring for critically ill patients.

Key Insights:

Werte aus dem Artikel:
QuidelOrtho Aktie 11,88 € 0,00%
  • One in five adults and one in ten children who contract sepsis die or go into hospice care
  • Delayed diagnosis and overuse of fluid resuscitation methods increase mortality rates
  • Inability to distinguish between bacterial and viral infections handicaps clinicians in making the right treatment decisions
  • Bacterial infections that go unrecognized may quickly escalate into sepsis
  • Swift diagnosis can mitigate these challenges as well as the overuse of antibiotics
  • Serial procalcitonin testing aids clinicians in identifying opportunities for antibiotic discontinuation or de-escalation
  • Early testing presents opportunities for quick intervention as well as targeted treatment

The conversation illuminates how rapid, actionable diagnostic information can aid emergency medicine physicians in making time-critical decisions in the ER.

Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
media@QuidelOrtho.com

QuidelOrtho Corporation

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/early-intervention-aids-emergency-medicine-teams-in-identifying-and-personalizing-sepsis-treatment-302888208.html

SOURCE QuidelOrtho Corporation



Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Themen im Trend

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren